The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: case series and review of the literature.

Septic shock occurs frequently in solid organ transplant (SOT) recipients. Standard therapy includes fluid resuscitation, the administration of antimicrobials, and source control of the infection. Adjunctive therapy with recombinant human activated protein C (rhaPC), also called drotrecogin alpha, is another treatment that is used in patients but has not been studied in SOT patients. Concerns regarding the use of this drug in this patient population include the risk of bleeding and the potential to adversely affect graft survival. Here we report the largest case series of SOT recipients with septic shock who received rhaPC. This was a retrospective chart review that looked at the impact of this drug in the SOT population. In this single-center study, we identified 17 patients with a SOT and septic shock who received rhaPC. Six of the patients underwent kidney transplants, 5 received lung transplants, 4 received cadaveric liver transplants, and 2 received combined kidney/pancreas transplants. The average APACHE II score was 26.6 ± 5.5; all patients were undergoing mechanical ventilation and receiving vasopressors at the time of rhaPC administration. Overall mortality in the group was 23.5% (4/17) at 28 days post infusion. All of the deaths were due to complications of septic shock. Allograft survival was present in 13/17 (76.5%) of the patients at 28 days. Bleeding occurred in 17.6% of patients (3/17). The use of rhaPC appears to be associated with a favorable effect on mortality, with the potential for increased risk of bleeding. Clinicians must balance this risk with the potential benefit of this drug until further research can be conducted.
AuthorsD J Funk, J Palma Vargas, J Tuttle-Newhall, E W Moretti
JournalTransplant infectious disease : an official journal of the Transplantation Society (Transpl Infect Dis) Vol. 13 Issue 6 Pg. 592-7 (Dec 2011) ISSN: 1399-3062 [Electronic] Denmark
PMID21794040 (Publication Type: Case Reports, Journal Article, Review)
Copyright© 2011 John Wiley & Sons A/S.
Chemical References
  • Anti-Infective Agents
  • Anti-Inflammatory Agents
  • Anticoagulants
  • Protein C
  • Recombinant Proteins
  • drotrecogin alfa activated
  • Adult
  • Aged
  • Anti-Infective Agents (adverse effects, therapeutic use)
  • Anti-Inflammatory Agents (therapeutic use)
  • Anticoagulants (therapeutic use)
  • Hemorrhage (chemically induced)
  • Humans
  • Immunosuppression Therapy (adverse effects)
  • Middle Aged
  • Organ Transplantation
  • Postoperative Complications (prevention & control)
  • Protein C (adverse effects, therapeutic use)
  • Recombinant Proteins (adverse effects, therapeutic use)
  • Retrospective Studies
  • Shock, Septic (drug therapy, etiology, immunology, prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: